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Abstract Ischemic preconditioning has been shown to improve
liver resistance to hypoxia/reperfusion damage. A signal pathway
involving A2A-adenosine receptor, Gi-proteins, protein kinase C
and p38 MAP kinase is responsible for the development of
hypoxic preconditioning in hepatocytes. However, the coupling of
this signal pathway with the mechanisms responsible for
cytoprotection is still unknown. We have observed that stimula-
tion of A2A-adenosine receptors or of p38 MAPK by CGS21680
or anisomycin, respectively, appreciably reduced intracellular
acidosis and Na+ accumulation developing during hypoxia. These
effects were reverted by p38 MAPK inhibitor SB203580 as well
as by blocking vacuolar proton ATPase with bafilomycin A1.
SB203580 and bafilomycin A1 also abolished the cytoprotec-
tive action exerted by both CGS21680 and anisomycin. We
propose that the stimulation of p38 MAPK by preconditioning
might increase hepatocyte resistance to hypoxia by activating
proton extrusion through vacuolar proton ATPase, thus limiting
Na+ overload promoted by Na+-dependent acid buffering
systems. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Recent studies have demonstrated that resistance to pro-
longed ischemic injury can be acquired by the liver following
one or more brief periods of ischemia followed by reperfusion
[1^4]. This phenomenon, known as hepatic ischemic precon-
ditioning, has received increasing interest since it increases the
success of liver transplantation in rats [5,6]. The mechanisms
leading to ischemic preconditioning have been extensively in-
vestigated in the heart, showing the involvement of the inter-
stitial accumulation of endogenous mediators, and particu-
larly of adenosine [7]. By interacting with myocardial
adenosine A1 receptors, adenosine triggers a signal pathway
that involves heterotrimeric Gi-proteins, phospholipase C and
the subsequent activation of protein kinase C (PKC) isoen-
zymes [7] as well as of a number of protein kinases including
stress-activated protein kinases (SAPKs) also known as c-Jun
N-terminal kinases (JNKs), extracellularly responsive kinases
(ERKs) and p38 mitogen-activated protein kinase (p38
MAPK) [8^10]. Adenosine has also been implicated to play
a role in liver preconditioning, however, di¡erently from the
heart, the stimulation of liver adenosine A2 receptors is re-
sponsible for the hepatoprotective action [6,11].
Experiments performed using isolated rat hepatocyte sus-
pensions demonstrated that the hepatoprotective action of
liver preconditioning observed in vivo can be reproduced in
vitro [4]. Using isolated hepatocytes we also observed that the
development of hypoxic preconditioning involved the sequen-
tial activation of A2A-adenosine receptor, Gi-proteins, phos-
pholipase C and N- and O-PKC isoenzymes [12]. The stimula-
tion of N- and O-PKCs was found to be coupled with the
speci¢c phosphorylation of p38 MAPK, whereas p38
MAPK inhibition reverted the e¡ects of preconditioning
[12]. Nonetheless, the coupling of p38 MAPK-mediated sig-
nals with the mechanisms preventing cell injury during hyp-
oxia is still poorly de¢ned.
Aim of this work has been to clarify how p38 MAPK stim-
ulation by preconditioning contributes the development of
hepatocyte protection against hypoxic injury. For this pur-
pose, preconditioning was induced in isolated hepatocytes
by the stimulation of A2A-adenosine receptor with the speci¢c
A2A-agonist CGS21680 as well as by the direct activation of
p38 MAPK with anisomycin A.
2. Materials and methods
2.1. Materials
Collagenase (type I), N-(2-hydroxyethyl)-piperazine-NP-(2-ethane-
sulfonic acid) (HEPES), chelerythrine, nigericin, phenylmethylsul-
phonyl £uoride, 2p-(2-carboxyethyl)phetyl-amino-5P-N-ethylcarboxy-
amido-adenosine (CGS21680), anisomycin A, SB203580 and
ba¢lomycin A1 were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Sodium probe benzofuran isophthalate (SBFI)-acetoxy-
methyl ester, 2P,7P-bis(carboxyethyl)-5,6-carboxy£uorescein-acetoxy-
methyl ester (BCECF-AM) and propidium iodide were supplied by
Molecular Probes (Eugene, OR, USA). All the other chemicals were
of analytical grade and were purchased from Merck (Darmstadt, Ger-
many).
2.2. Hepatocyte isolation and treatments
Isolated rat hepatocytes were prepared by collagenase liver perfu-
sion [13] of fed male Wistar rats (180^250 g weight) (Nossan, Corez-
zana, Italy). The use and the care of the animals were approved by
the Italian Ministry of Health and by the University Commission for
Animal Care following the criteria of the Italian National Research
Council. Cell viability, estimated at the beginning of the experiments,
ranged between 85 and 90%. Hepatocytes were suspended in Krebs^
Henseleit^HEPES (KKH) bu¡er (¢nal cell density of 106/ml) contain-
ing 118 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 mmol/l KH2PO4, 1.3
mmol/l CaCl2, 25 mmol/l NaHCO33 and 20 nmol/l HEPES at pH
7.4. Hepatocyte treatment with the di¡erent agents was performed
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by 15 min pre-incubation at 37‡C before 90 min incubation at 37‡C in
sealed bottles under 95% N2/5% CO2 atmosphere. Cell viability was
estimated by microscope counting the hepatocyte excluding trypan
blue and by the determination of nuclear £uorescence staining with
propidium iodide according to Gores et al. [14].
2.3. Measurement of lactate production
Hepatocyte lactate production was measured enzymatically accord-
ing to Gutmann and Wahlefeld [15] in cell suspensions (3U106 cells/
ml) incubated 30 min at 37‡C under hypoxic and normoxic conditions
and with or without the preconditioning agents CGS21680 and ani-
somycin A.
2.4. Measurement of cytosolic pH
Cytosolic pH was measured using the £uorescent indicator
dye 2P,7P-bis(carboxyethyl)-5,6-carboxy£uorescein-acetoxymethyl ester
(BCECF-AM). Brie£y, isolated hepatocytes (3U106 cells/ml) were
loaded with BCECF-AM (5 Wg/ml) by 30 min incubation at 25‡C in
a modi¢ed KHH bu¡er containing 2% bovine serum albumin and
10 mmol/l glucose. After washing, the cells were re-suspended in fresh
KKH medium and treated with preconditioning agents. Precon-
ditioned and non-preconditioned hepatocytes were then subjected
to 20 min of hypoxia. At the end of the incubation, 2 ml aliquots
were taken and centrifuged for 1 min at 800Ug. Cell pellets were re-
suspended in fresh medium and the £uorescence was determined at
450/500 nm wavelength pair using a Hitaki 4500 spectro£uorimeter.
Calibration values were obtained for each experiment by incubating
hepatocytes in media at di¡erent pH containing 120 mmol/l K and
10 Wmol/l of the K/H ionophore nigericin.
2.5. Measurement of intracellular Na+ content
For the measurement of intracellular Na content isolated hepato-
cytes were loaded with the £uorescent Na probe benzofuran iso-
phthalate-acetoxymethyl ester (SBFI-AM; 10 Wmol/l ¢nal concentra-
tion in DMSO) by 60 min incubation at 25‡C in KHH bu¡er
containing 2% bovine serum albumin and 10 mmol/l glucose. After
washing, the cells were re-suspended in fresh KKH medium and pre-
conditioned as described above. At each time point, 2 ml aliquots of
the cell suspension were taken and centrifuged for 1 min at 800Ug.
Cell pellets were re-suspended in fresh medium and the £uorescence
was determined at using Hitaki 4500 spectro£uorimeter set at 345 and
385 nm excitation and at 510 nm emission wavelengths. The ratio of
£uorescence values obtained with 345 nm and 385 nm excitation were
calculated after correction for spontaneous SBFI £uorescence. Cali-
bration of SBFI £uorescence was performed by placing the hepato-
cytes into solutions of known Na concentration in the presence of
the Na ionophore gramicidin D (2 Wmol/l).
2.6. Data analysis and statistical calculations
The data were expressed as means þ standard deviation (S.D.). Sta-
tistical analysis was performed by Instat-3 statistical software (Graph-
Pad Software Inc, San Diego, CA, USA) using one-way ANOVA test
with Bonferroni’s correction for multiple comparisons when more
than two groups were analyzed. Distribution normality of all the
groups was preliminary veri¢ed by Kolmogorov and Smirnov test.
Signi¢cance was taken at 5% level.
3. Results and discussion
Previous studies have shown that the prevention of intra-
cellular acidosis is a consistent feature in preconditioned tis-
sues [7]. Table 1 demonstrates that a signi¢cant improvement
of intracellular pH can be observed in hypoxic hepatocytes
following the induction of preconditioning by the stimulation
of adenosine A2 receptors with CGS21680 (1 Wmol/l). A sim-
ilar e¡ect was also obtained by promoting the activation of
p38 MAPK with 500 ng/ml anisomycin A, whereas SB203580
(2 Wmol/l), a selective inhibitor of p38 MAPK reverted the
action of both CGS21680 and anisomycin A on hepatocyte
pH (Table 1). The possibility that the activation of p38
MAPK might prevent hypoxic acidosis by modulating the
acid production during hypoxia was excluded, since lactate
accumulation was not di¡erent between control hepatocytes
(13.1 þ 0.97 nmol/mg protein/min) and CGS21680- or aniso-
mycin A-treated cells (12.6 þ 1.23 and 14.3 þ 1.71 nmol/mg
protein/min, respectively). The activation of proton extrusion
through Na/H exchanger or vacuolar proton ATPase (V-
ATPase) has been proposed to account for the attenuation of
intracellular acidosis in preconditioned myocardiocytes
[16,17]. In isolated hepatocytes, the block of Na/H ex-
changer with 5-(N,N-dimethyl)-amiloride (DMA) (10 Wmol/l)
did not appreciably a¡ect the attenuation of intracellular
acidosis produced by CGS21680 and anisomycin A (Table
1). Conversely, the addition of ba¢lomycin A1 (50 nmol/l), a
speci¢c inhibitor of V-ATPase [18], completely abolished the
protection exerted by the above agents against hypoxic acido-
sis (Table 1).
V-ATPases are a family of widely distributed ATP-driven
Table 1
Changes in intracellular pH in hypoxic hepatocytes following the stimulation of p38 MAPK activity and e¡ect of the modulation of Na/H
exchanger and V-ATPase
Treatments T0 20 min hypoxia
None 7.37 þ 0.020 7.04 þ 0.084a
CGS21680 1 Wmol/l 7.37 þ 0.004 7.30 þ 0.018b
Anisomycin A 500 ng/ml 7.35 þ 0.130 7.29 þ 0.111b
SB203580 2 Wmol/l 7.37 þ 0.011 7.01 þ 0.038a
CGS21680+SB203580 7.37 þ 0.088 7.06 þ 0.042a;c
Anisomycin A+SB203580 7.36 þ 0.106 7.09 þ 0.121a;c
5-(N,N-dimethyl)-amiloride 10 Wmol/l 7.36 þ 0.082 6.99 þ 0.062a
CGS21680+5-(N,N-dimethyl)-amiloride 7.37 þ 0.118 7.29 þ 0.216b
Anisomycin A+5-(N,N-dimethyl)-amiloride 7.37 þ 0.078 7.27 þ 0.135b
Ba¢lomycin A1 50 nmol/l 7.36 þ 0.065 7.02 þ 0.057a;c
CGS21680+ba¢lomycin A1 7.36 þ 0.079 7.02 þ 0.118a;c
Anisomycin A+ba¢lomycin A1 7.37 þ 0.108 7.09 þ 0.31a;c
Isolated hepatocytes suspended in KKH bu¡er were loaded with the £uorescent indicator dye 2P,7P-bis(carboxyethyl)-5,6-carboxy £uorescein-
acetoxymethyl ester (BCECF-AM) (5 Wg/ml) by 15 min incubation at 37‡C. After washing, the cells were re-suspended in fresh KHH bu¡er
and incubated 15 min with 1 Wmol/l CGS21680 or 500 ng/ml anisomycin A. CGS21680- or anisomycin A-treated and untreated cells were then
incubated 20 min under 95% N2/5% CO2 atmosphere with or without the di¡erent inhibitors. In order to block p38 MAPK, hepatocytes were
pre-treated with SB203580 5 min before the addition of CGS21680 or anisomycin A. The results are means of three^¢ve di¡erent experi-
ments þ S.D.
aStatistical signi¢cance P6 0.02 versus hepatocytes before the hypoxic treatment.
bStatistical signi¢cance P6 0.02 versus control hepatocytes incubated under hypoxic conditions.
cStatistical signi¢cance P6 0.02 versus CGS21680- or anisomycin A-treated cells.
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proton pumps that are responsible for the acidi¢cation of
intracellular compartments, such as synaptic vesicles, lyso-
somes and endosomes [19]. In several cell types, including
phagocytes and hepatocytes, V-ATPases are present also in
the plasma membranes, where they contribute in controlling
intracellular pH [20,21]. The mechanisms regulating V-ATP-
ase activity have been extensively investigated showing the
involvement of reversible subunits assembly and disul¢de
bond formation [22]. Nonetheless, Nordstro«m and co-workers
have reported that PKC-mediated signaling can also be re-
sponsible for plasma membrane V-ATPase regulation during
rat phagocyte metabolic burst [23]. Taken together these re-
sults suggested that the stimulation of p38 MAPK in precon-
ditioned hepatocytes improved cellular pH during hypoxia by
favoring proton extrusion through vacuolar proton ATPase.
One of the consequences of hypoxic acidosis is an increased
Na in£ux due to the activation of acid bu¡ering systems
involving Na/H exchanger and Na/HCO33 co-transporter
[24]. Such an e¡ect, in combination with the impairment of
Na e¥ux through Na/K ATPase due to ATP depletion,
leads to a progressive accumulation of Na within the cells.
The measurement of intracellular Na levels during hypoxic
incubation demonstrated a signi¢cant reduction of Na accu-
mulation in hepatocytes receiving CGS21680 (Fig. 1) or ani-
somycin A (Fig. 2). The e¡ects of CGS21680 and of aniso-
mycin A on intracellular Na were not a¡ected by blocking
Fig. 1. Stimulation of adenosine A2 receptors by CGS21680 reduces intracellular Na accumulation (panel A) and cell death (panel B) in iso-
lated hepatocytes exposed to hypoxia: e¡ect of Na/H ionophore monensin and of the inhibition of p38 MAPK and of V-ATPase with, re-
spectively, SB203580 or ba¢lomycin A1. Isolated rat hepatocytes suspended in KKH bu¡er were pre-incubated 5 min at 37‡C with 2 Wmol/l
SB203580 or 15 min with 50 nmol/l ba¢lomycin A1, before the addition of 1 Wmol/l CGS21680. Monensin 10 Wmol/l was added just before hy-
poxic incubation. Hepatocyte viability and intracellular Na content were assessed by, respectively, propidium iodide and sodium probe benzo-
furan isophthalate (SBFI) £uorescence during 90 min incubation under 95% N2/5% CO2 atmosphere. The results are means of four^¢ve di¡er-
ent experiments. Statistical signi¢cance: *P6 0.001 versus hepatocytes not receiving CGS21680 or incubated with CGS21680 in the presence of
monensin, ba¢lomycin or SB203580.
Fig. 2. Activation of p38 MAPK by anisomycin A reduces intracellular Na accumulation (panel A) and cell death (panel B) in isolated hepa-
tocytes exposed to hypoxia: e¡ect of Na/H ionophore monensin and of the inhibition of p38 MAPK and of V-ATPase with, respectively,
SB203580 or ba¢lomycin A1. Isolated rat hepatocytes suspended in KKH bu¡er were pre-incubated 5 min at 37‡C with 2 Wmol/l SB203580 or
15 min with 50 nmol/l ba¢lomycin A1, before the addition of or 500 ng/ml anisomycin A. Monensin 10 Wmol/l was added just before hypoxic
incubation. Hepatocyte viability and intracellular Na content were assessed by, respectively, propidium iodide and sodium probe benzofuran
isophthalate (SBFI) £uorescence during 90 min incubation under 95% N2/5% CO2 atmosphere. The results are means of four^¢ve di¡erent ex-
periments. Statistical signi¢cance: *P6 0.001 versus hepatocytes not receiving anisomycin A or incubated with anisomycin A in the presence of
monensin, ba¢lomycin or SB203580.
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Na/K ATPase with ouabain (not shown). Conversely, in-
hibiting p38 MAPK with SB203580 or blocking V-ATPase
with ba¢lomycin A1 reverted the protection against Na ac-
cumulation induced by either CGS21680 (Fig. 1) or anisomy-
cin A (Fig. 2). This suggests that, by preventing intracellular
acidosis, the activation of p38 MAPK might limit Na in£ux
through Na-dependent acid bu¡ering systems. Recent stud-
ies have indicated that the activation of Na-K-Cl3 co-
transporter and of non-selective cation channels are also in-
volved in promoting Na in£ux within liver cell exposed to
hypoxia or to oxidative stress [25,26]. At this stage it can not
be excluded that p38 MAPK-mediated signals might also reg-
ulate these latter Na transport mechanisms in hepatocyte
plasma membranes.
We have previously reported that the derangement of cel-
lular osmotic equilibrium consequent to Na overload pre-
ceded hepatocyte killing by metabolic inhibition [13,27]. Fur-
thermore, conditions that prevented Na overload were found
protective against the cytotoxic e¡ects of hypoxia, mitochon-
drial damage or reperfusion injury [13,28,29]. Figs. 1 and 2
show that SB203580 and ba¢lomycin A1 reverted the protec-
tion given by CGS21680 or anisomycin A against hepatocyte
killing during hypoxia. A similar e¡ect was also seen follow-
ing the addition of Na ionophore monensin (Figs. 1 and 2).
Nonetheless, monensin, SB203580 and ba¢lomycin A1 did not
a¡ect Na content and cell viability when added to hepato-
cytes maintained under normoxic conditions (not shown).
In conclusion, we propose that the stimulation of p38
MAPK by preconditioning might increase hepatocyte resis-
tance to hypoxia by activating proton extrusion through vac-
uolar proton ATPase, limiting Na in£ux promoted by Na-
dependent acid bu¡ering systems. Recently, inhibition of casp-
ase 3 has been reported to prevent hepatocyte and sinusoidal
endothelial cell apoptosis in preconditioned mouse livers [3].
This latter observation is compatible with the present ¢ndings,
since modulation of V-ATPase can stimulate apoptosis by
enhancing p53 expression and caspase 3 activity [30].
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